Adhesive polymer and medical adhesive patch

Patent metadata

Field	Value
Publication number	US-11077069-B2
Application number	US-201615764422-A
Country	US
Kind code	B2
Filing date	Sep 30, 2016
Priority date	Sep 30, 2015
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

The present invention provides a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9% by mass of whole structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers containing a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a weakly basic monomer; and a medical patch containing an adhesive composition containing a salt of a basic drug and the star-shaped acrylic block polymer as an adhesive that exhibits high drug efficacy, that does not cause a decrease in adhesive property of an adhesive base due to an additive, and that causes less skin irritation.

First claim

The invention claimed is:

1. A medical patch comprising an adhesive composition comprising at least one salt of a basic drug and an adhesive,
wherein the adhesive is a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a polyvalent mercaptan residue situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9% by mass of whole structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a structural unit having a copolymer structure of polymerizable monomers comprising at least one (meth)acrylic acid alkyl ester having 7-17 carbon atoms and at least one weakly basic monomer selected from the group consisting of dimethylaminoethyl (meth)acrylate, diethylaminoethyl (meth)acrylate, dimethylaminoethyl (meth)acrylate quaternary ammonium salt, dimethylaminopropyl acrylamide, diethylaminopropyl acrylamide, (meth)acrylamide, N-methyl(meth)acrylamide and N-propyl(meth)acrylamide;
wherein the at least one salt of the basic drug is at least one selected from the group consisting of fentanyl citrate, morphine sulfate, oxycodone hydrochloride, buprenorphine hydrochloride, oxybutynin hydrochloride, tamsulosin hydrochloride, tolterodine tartrate, rasagiline mesylate, pergolide mesylate, amantadine hydrochloride, trihexyphenidyl hydrochloride, ropinirole hydrochloride, lidocaine hydrochloride, procaine hydrochloride, donepezil hydrochloride, memantine hydrochloride, tandospirone citrate, methylphenidate hydrochloride, lurasidone hydrochloride, chlorpromazine hydrochloride, imipramine hydrochloride, asenapine maleate, salbutamol sulfate, clenbuterol hydrochloride, tulobuterol hydrochloride, procaterol hydrochloride, butorphanol tartrate, perisoxal citrate, enalapril maleate, propranolol hydrochloride, bisoprolol hydrochloride, clonidine hydrochloride, diltiazem hydrochloride, verapamil hydrochloride, isosorbide dinitrate, ketotifen fumarate, chlorpheniramine maleate, azelastine hydrochloride, diphenhydramine hydrochloride, granisetron hydrochloride, ramosetron hydrochloride, palonosetron hydrochloride and ondansetron hydrochloride; and
wherein the adhesive composition does not comprise an additive used for converting the at least one salt of the basic drug into a free base.

2. The medical patch according to claim 1 , wherein the content of the at least one weakly basic monomer relative to a non-volatile content in the adhesive is 0.1-39% by mass.

3. The medical patch according to claim 1 , wherein the content of the at least one salt of the basic drug is 0.1-50% by mass, and the content of the adhesive is 50-99.9% by mass in the adhesive composition.

4. The medical patch according to claim 1 , wherein the at least one (meth)acrylic acid alkyl ester having 7-17 carbon atoms is at least one selected from the group consisting of (meth)acrylic acid butyl ester, (meth)acrylic acid t-butyl ester, (meth)acrylic acid pentyl ester, (meth)acrylic acid hexyl ester, (meth)acrylic acid heptyl ester, (meth)acrylic acid octyl ester, (meth)acrylic acid isooctyl ester, (meth)acrylic acid nonyl ester, (meth)acrylic acid isononyl ester, (meth)acrylic acid decyl ester, (meth)acrylic acid undecyl ester, (meth)acrylic acid dodecyl ester and (meth)acrylic acid 2-ethylhexyl ester.

5. The medical patch according to claim 1 , wherein the at least one salt of the basic drug is at least one selected from the group consisting of rasagiline mesylate and asenapine maleate.

6. The medical patch according to claim 1 , wherein the at least one weakly basic monomer is selected from the group consisting of dimethylaminoethyl methacrylate and dimethylaminopropyl acrylamide.

Assignees

• Teikoku Seiyaku Kk
• Nippon Catalytic Chem Ind

Inventors

• Kawakami Satoshi
• Sogabe Manabu
• Shibata Taiki
• Horikawa Yasushi
• Hasegawa Hiroaki

Classifications

• A61K45/00

  Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/167

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

• A61K31/48

  Ergoline derivatives, e.g. lysergic acid, ergotamine · CPC title

• A61K47/32

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title

• A61K31/4468

  having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl · CPC title